|
CA2019714A1
(en)
|
1989-06-27 |
1990-12-27 |
Richard A. Chizzonite |
Process for the determination of interleukins
|
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
|
JP2002528389A
(ja)
|
1998-08-21 |
2002-09-03 |
イエダ リサーチ アンド デベロップメント カンパニー リミテッド |
Ｉｌ−２及びその類似体から誘導される抗炎症性ペプチド
|
|
HUP0204475A2
(en)
|
2000-02-11 |
2003-04-28 |
Merck Patent Gmbh |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
KR20030064275A
(ko)
|
2000-06-29 |
2003-07-31 |
메르크 파텐트 게엠베하 |
면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
|
|
DK1454138T3
(da)
|
2001-12-04 |
2012-02-13 |
Merck Patent Gmbh |
Immunocytokiner med moduleret selektivitet
|
|
US7569215B2
(en)
|
2003-07-18 |
2009-08-04 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
|
AU2013205030B2
(en)
*
|
2004-12-22 |
2016-05-12 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
JP2008528621A
(ja)
|
2005-01-27 |
2008-07-31 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド |
腎細胞ガンを処置するための方法
|
|
US7667076B2
(en)
|
2005-09-14 |
2010-02-23 |
Regents Of The University Of California |
Amide forming chemical ligation
|
|
WO2009061853A2
(en)
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
|
AU2010206840B2
(en)
|
2009-01-21 |
2015-02-05 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
WO2012065086A1
(en)
|
2010-11-12 |
2012-05-18 |
Nektar Therapeutics |
Conjugates of an il-2 moiety and a polymer
|
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
CA2860170C
(en)
|
2010-12-22 |
2022-06-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
SG192673A1
(en)
|
2011-02-10 |
2013-09-30 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
EP2723380B1
(en)
|
2011-06-24 |
2019-08-21 |
Stephen D. Gillies |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
|
US20160107999A1
(en)
|
2013-05-24 |
2016-04-21 |
Synaffix B.V. |
Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
|
|
US10266502B2
(en)
|
2014-01-24 |
2019-04-23 |
Synaffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
PT3102595T
(pt)
|
2014-02-06 |
2019-01-11 |
Hoffmann La Roche |
Proteínas de fusão de interleucina-2 e suas utilizações
|
|
KR102410090B1
(ko)
|
2014-02-21 |
2022-06-16 |
넥타르 테라퓨틱스 (인디아) 프라이빗 리미티드 |
항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제
|
|
WO2015164815A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
|
AU2015301936B2
(en)
|
2014-08-11 |
2019-03-07 |
Delinia, Inc. |
Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
|
|
WO2016025647A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
|
|
CA2957717C
(en)
|
2014-08-12 |
2021-10-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
|
DK3186283T3
(da)
|
2014-08-29 |
2020-03-02 |
Hoffmann La Roche |
Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1
|
|
CN117659160A
(zh)
|
2015-09-11 |
2024-03-08 |
小利兰·斯坦福大学托管委员会 |
生物相关正交细胞因子/受体对
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
US10888603B2
(en)
|
2016-02-12 |
2021-01-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating cancer cells expressing tumor-associated integrins
|
|
JP6911044B2
(ja)
|
2016-03-16 |
2021-07-28 |
シェ、ヤンホイＸｉｅ Ｙａｎｈｕｉ |
呼吸器系疾患の治療のためのグルココルチコイドとポリエチレングリコール修飾インターロイキン２の組合せ
|
|
JP7422480B2
(ja)
|
2016-05-04 |
2024-01-26 |
アムジエン・インコーポレーテツド |
制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
|
|
US11395853B2
(en)
|
2016-06-23 |
2022-07-26 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
|
|
JP7128121B2
(ja)
|
2016-06-28 |
2022-08-30 |
ヴェンタナ メディカル システムズ， インク． |
Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用
|
|
EP3538548A4
(en)
|
2016-11-08 |
2020-08-19 |
Delinia, Inc. |
IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
|
KR20190105568A
(ko)
|
2016-11-10 |
2019-09-17 |
넥타르 테라퓨틱스 |
종양의 면역 요법적 치료 방법
|
|
CU24483B1
(es)
|
2016-11-15 |
2020-04-02 |
Ct Inmunologia Molecular |
Método para incrementar los niveles de secreción de la interleucina-2
|
|
ES2973548T3
(es)
|
2016-12-22 |
2024-06-20 |
Cue Biopharma Inc |
Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
|
|
EP3573651A4
(en)
*
|
2017-01-27 |
2020-10-14 |
NGM Biopharmaceuticals, Inc. |
GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USE
|
|
MY201482A
(en)
|
2017-04-03 |
2024-02-26 |
Hoffmann La Roche |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
CN110505883A
(zh)
|
2017-04-13 |
2019-11-26 |
豪夫迈·罗氏有限公司 |
供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂
|
|
US10676516B2
(en)
|
2017-05-24 |
2020-06-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
CN111201035A
(zh)
|
2017-06-19 |
2020-05-26 |
梅迪塞纳医疗股份有限公司 |
Il-2超激动剂、激动剂及其融合体的用途和方法
|
|
US20190023760A1
(en)
|
2017-07-24 |
2019-01-24 |
Eth Zurich |
Method for preparing interleukin-2 or interleukin-2 analogues
|
|
KR20240141853A
(ko)
|
2017-08-03 |
2024-09-27 |
신톡스, 인크. |
자가면역 질환의 치료를 위한 사이토카인 접합체
|
|
WO2019036031A2
(en)
|
2017-08-17 |
2019-02-21 |
Nektar Therapeutics |
IMMUNOTHERAPEUTIC METHOD FOR TUMOR TREATMENT
|
|
KR102777151B1
(ko)
|
2017-11-21 |
2025-03-05 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
인터루킨-2의 부분 효능제
|
|
JP2021505156A
(ja)
|
2017-12-06 |
2021-02-18 |
パンディオン・オペレーションズ・インコーポレイテッド |
標的化免疫寛容
|
|
IL275426B2
(en)
|
2017-12-19 |
2025-03-01 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
|
WO2019129053A1
(zh)
|
2017-12-26 |
2019-07-04 |
南京金斯瑞生物科技有限公司 |
以抗体Fc区为骨架的融合蛋白二聚体及其应用
|
|
EP3762406A2
(en)
|
2018-03-09 |
2021-01-13 |
Askgene Pharma, Inc. |
Cytokine prodrugs
|
|
BR112020021564A2
(pt)
*
|
2018-05-21 |
2021-03-02 |
Nektar Therapeutics |
estimulador de treg seletivo rur20kd-il-2 e composições relacionadas
|
|
KR20250156190A
(ko)
*
|
2018-06-22 |
2025-10-31 |
큐진 인크. |
인터루킨-2 변이체 및 이의 사용 방법
|
|
CA3111576A1
(en)
|
2018-09-11 |
2020-03-19 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and their uses
|
|
CA3098930A1
(en)
|
2018-09-21 |
2020-03-26 |
Innovent Biologics (Suzhou) Co., Ltd. |
Novel interleukin-2 and use thereof
|
|
EP3923974A4
(en)
|
2019-02-06 |
2023-02-08 |
Synthorx, Inc. |
IL-2 CONJUGATES AND METHODS OF USE THEREOF
|
|
US20220233711A1
(en)
|
2019-05-17 |
2022-07-28 |
Shenzhen Enduring Biotech, Ltd. |
Bispecific t-cell engager with cleavable cytokines for targeted immunotherapy
|
|
WO2020252421A2
(en)
|
2019-06-14 |
2020-12-17 |
Cugene, Inc. |
Novel interleukin-2 variants and bifunctional fusion molecules thereof
|
|
KR20220044534A
(ko)
|
2019-08-13 |
2022-04-08 |
엘피스 바이오파마슈티컬즈 |
조작된 인터류킨-2 수용체 베타 효능제
|
|
EP4013777A4
(en)
|
2019-08-15 |
2024-01-17 |
Cytimm Therapeutics, Inc. |
MODIFIED INTERLEUKIN 2 (IL-2) POLYPEPTIDES, CONJUGATES AND USES THEREOF
|
|
CN114555128A
(zh)
|
2019-08-15 |
2022-05-27 |
新索思股份有限公司 |
采用il-2缀合物的免疫肿瘤学组合疗法
|
|
CN114853874B
(zh)
*
|
2019-09-10 |
2024-05-17 |
中国医学科学院北京协和医院 |
靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
|
|
US12234271B2
(en)
*
|
2019-09-10 |
2025-02-25 |
Synthorx, Inc. |
Il-2 conjugates and methods of use to treat autoimmune diseases
|
|
MX2022007202A
(es)
|
2019-12-13 |
2022-10-07 |
Cugene Inc |
Fármacos bioactivables a base de citocinas y metodos de uso de los mismos.
|
|
US11633488B2
(en)
|
2020-01-10 |
2023-04-25 |
Bright Peak Therapeutics Ag |
Modified IL-2 polypeptides and uses thereof
|
|
PE20231648A1
(es)
|
2020-04-22 |
2023-10-17 |
Merck Sharp And Dohme Llc |
CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DIMERO DEL RECEPTOR DE INTERLEUCINA 2 byc Y CONJUGADOS CON UN POLIMERO HIDROSOLUBLE NO PEPTIDICO
|
|
WO2021236474A1
(en)
|
2020-05-22 |
2021-11-25 |
Merck Sharp & Dohme Corp. |
Novel processes for preparing conjugates of the il-2 protein
|
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
|
JP2024504372A
(ja)
|
2021-01-22 |
2024-01-31 |
エルピス・バイオファーマシューティカルズ |
抗ｐｄ－ｌ１モノクローナル抗体及びインターロイキン１５（ｉｌ－１５）、インターロイキン１５受容体１５アルファまたはインターロイキン２との融合タンパク質
|
|
US20230201365A1
(en)
|
2021-07-09 |
2023-06-29 |
Bright Peak Therapeutics Ag |
Modified cd20 antibodies and uses thereof
|
|
US20230201364A1
(en)
|
2021-07-09 |
2023-06-29 |
Bright Peak Therapeutics Ag |
Antibody conjugates and manufacture thereof
|
|
AU2022306974A1
(en)
|
2021-07-09 |
2024-01-04 |
Bright Peak Therapeutics Ag |
Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
|
|
EP4366781A1
(en)
|
2021-07-09 |
2024-05-15 |
Bright Peak Therapeutics AG |
Checkpoint inhibitors conjugated to il-2, and uses thereof
|
|
WO2023281480A1
(en)
|
2021-07-09 |
2023-01-12 |
Bright Peak Therapeutics Ag |
Conjugates of checkpoint inhibitors with il-2, and uses thereof
|
|
WO2023161857A1
(en)
|
2022-02-23 |
2023-08-31 |
Bright Peak Therapeutics Ag |
Bifunctional cytokine compositions
|
|
WO2023202035A1
(zh)
*
|
2022-04-20 |
2023-10-26 |
北京大学宁波海洋药物研究院 |
受体偏向的peg化il-2变体组合及其应用
|
|
US20240417436A1
(en)
|
2023-01-11 |
2024-12-19 |
Bright Peak Therapeutics Ag |
Conditionally activated immunocytokines and methods of use
|
|
US20240376170A1
(en)
|
2023-01-11 |
2024-11-14 |
Bright Peak Therapeutics Ag |
Conditionally activated proteins and methods of use
|